Low-level Light Therapy Versus Intense Pulsed Light to Prevent Iatrogenic Dry Eye Disease After Cataract Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: LLLT, IPL.
- Who it may be relevant to
- Registry conditions: Cataract Surgery, Eye Dryness. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Low-level Light Therapy Versus Intense Pulsed Light to Prevent Iatrogenic Dry Eye Disease After Cataract Surgery: a Randomised Controlled Trial
Overview
Dry eye disease (DED) is a frequent ocular surface disease (OSD) of multifactorial origin, characterised by disruption of tear film homeostasis and associated with ocular discomfort and/or visual disturbance. Cataract surgery, which is one of the most often performed interventions worldwide, can induce or worsen the symptoms of DED. Despite lack of guidelines on DED prophylaxis before cataract surgery in the general population, there is a growing interest in this topic due to the high prevalence of postoperative DED. A recent randomised controlled trial (RCT) with one month follow-up showed that prophylactic low-level light therapy (LLLT) before and after cataract surgery in patients without pre-existing DED significantly improved postoperative tear film stability, as well as reduced ocular discomfort, compared to no prophylaxis. Apart from LLLT, another light-based treatment for DED is intense pulsed light (IPL); the treatments have shown favourable outcomes in the management of DED, both as stand-alone choices or in combination.
Detailed description
Dry eye disease (DED) is a frequent ocular surface disease (OSD) of multifactorial origin, characterised by disruption of tear film homeostasis and associated with ocular discomfort and/or visual disturbance. Cataract surgery, which is one of the most often performed interventions worldwide, can induce or worsen the symptoms of DED. Despite lack of guidelines on DED prophylaxis before cataract surgery in the general population, there is a growing interest in this topic due to the high prevalence of postoperative DED. A recent randomised controlled trial (RCT) with one month follow-up showed that prophylactic low-level light therapy (LLLT) before and after cataract surgery in patients without pre-existing DED significantly improved postoperative tear film stability, as well as reduced ocular discomfort, compared to no prophylaxis. Apart from LLLT, another light-based treatment for DED is intense pulsed light (IPL); the treatments have shown favourable outcomes in the management of DED, both as stand-alone choices or in combination.
There is currently no comparative data available which would allow to choose between LLLT and IPL as prophylaxis for iatrogenic DED after cataract surgery.
The primary objective of this RCT is to compare LLLT versus IPL as prophylaxis for iatrogenic DED after cataract surgery in terms of patient-reported symptoms of eye dryness at 3 months.
Interventions
- Procedure LLLT
Patients in the LLLT group will receive 3 sessions of LLLT treatment with Eye-light device (Espansione Group S.p.A., Bologna, Italy) 7 days before phacoemulsification (D-7), 7 days after phacoemulsification (D+7), and 30 days after phacoemulsification (D+30). Each session will consist of 15 minutes of light treatment using a wavelength of 625±40 nm and maximum power of 10 W (maximal total fluence of 32 J/cm2 ± 20% per session) applied on the periorbital region. The patients will be asked to clos - Procedure IPL
Patients in the IPL group will receive 3 sessions of IPL treatment with OptiClear device (Alma Lasers GmbH, Nuremberg, Germany) at D-7, D+7, and D+30. Each session will comprise 90 homogenously spaced pulses of light (wavelength of 550-650 nm, pulse time 10,12 or 15 ms, pulse repetition rate 1-2 Hz) using an energy density of 8-12 J/cm2 adjusted to Fitzpatrick skin type according to the manufacturer's recommendations. The treatment will be applied to the lower eyelid region. Ultrasound gel, as w
Primary outcome measures
- Patient-reported symptoms of eye dryness (OSDI) [Time frame: 3 months after cataract surgery]
Secondary outcome measures (10)
- Patient-reported symptoms of eye dryness (OSDI) [Time frame: 1 week, 1 month after cataract surgery]
- patient-reported symptoms of eye dryness (SANDE) [Time frame: 1 week after, 1 month after and 3 months after the surgery]
- Non-invasive tear film break-up time (NIBUT) [Time frame: 1 week, 1 and 3 months after cataract surgery]
- Ocular redness [Time frame: 1 week after, 1 and 3 months after cataract surgery]
- Meibomian gland (MG) atrophy [Time frame: 1 week, 1 and 3 months after cataract surgery]
- Fluorescein corneal staining (FCS) [Time frame: 1 week, 1 and 3 months after cataract surgery]
- Eyelid telangiectasias [Time frame: 1 week after, 1 and 3 months after cataract surgery]
- Meibomian expressiblity and quality [Time frame: 1 week, 1 and 3 months after cataract surgery,]
- Ultrasound energy delivered [Time frame: Intra-operatively]
- Adverse Events [Time frame: 0 to 3 months after cataract surgery]
Eligibility criteria
Inclusion criteria
- aged ≥50 years
- scheduled for bilateral cataract surgery by phacoemulsification
- without current DED treatment, including eye drops, for at least two months before the inclusion
- with preoperative OSDI ≤22 points, indicating absence of DED or mild DED
- who signed the informed consent and are willing to comply with the protocol requirements based on the investigator's judgment
- affiliated with a social security scheme
- with an ability to answer questionnaires and to communicate freely in French.
Exclusion criteria
- set to undergo implantation of a multifocal intraocular lens
- using contact lenses
- with any of the following in the included eye: (i) age-related macular degeneration (AMD), (ii) previous ocular surgery, (iii) abnormal clinical exam of the ocular surface or (iv) undergoing any ocular treatment
- with systemic contraindications, including autoimmune diseases (e.g., Sjögren syndrome)
- with general contraindications for LLLT or IPL treatment: dark pigmented skin (Fitzpatrick grade ≥5), skin photosensitivity (regardless if innate, pathological or medically-induced), or neurological light sensitivity (e.g. epilepsy, light-induced migraines)
- with contraindications for LLLT or IPL treatment limited to the treatment area: history of skin cancer, skin pigmented lesions, as well as fixed/permanent skin piercings, face tattoos, semi-permanent make-up (including microblading) or skin defects
- with any concomitant disease or disorder which, in the opinion of the investigator, may put the patient at risk or may influence the result of the study
- with protected status under articles L1121-6, LL121-8 and L1122-2 of the French Public Health Code
- who cannot comply with the protocol requirements based on the investigator's judgment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Prevention
Study locations
France · 1 center
- Clinique Trenel — Sainte-Colombe
Identifiers
NCT: NCT07055022 · 2025-A00858-41